Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP212525 in Healthy Volunteers

Sponsor
Daewoong Pharmaceutical Co. LTD.
Study ID
NCT06736587
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Autoimmune Diseases

Eligibility Criteria

Sex
ALL
Age
19 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • DWP212525 XXmg — DRUG
    DWP212525 XXmg
  • DWP212525 placebo — DRUG
    DWP212525 placebo

Study Details

The safety and tolerability of single and multiple administration of DWP212525

Key Dates

First listed
Dec 16, 2024
Start date
Dec 10, 2024
Status verified
Dec 2025
Primary completion
Dec 30, 2026
Completion
Mar 30, 2027

Study Design

Enrollment
84 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort1
  • Experimental: Cohort2
  • Experimental: Cohort3
  • Experimental: Cohort4
  • Experimental: Cohort5
  • Experimental: Cohort6
  • Experimental: Cohort7
  • Experimental: Cohort8
  • Experimental: Cohort9
  • Experimental: Cohort10
  • Experimental: Cohort 11

Primary Outcome Measure

PK profiles of DWP212525 [ Time Frame: Day 1 ]

Related Studies